Telangana pharma blast: At least 13 dead, 34 injured; five-member panel, experts to probe incident
At least 13 people died and 34 persons were injured on Monday in an explosion at the Sigachi Industries' pharma plant in Telangana's Sangareddy district.
About 90 people were working in the plant when the blast took place, reportedly due to a suspected chemical reaction, which also triggered a fire, Health Minister Damodara Raja Narasimha told reporters.
Later in the evening, a police official told PTI that another body was extricated from the debris, bringing the total number of deaths to 13.
'Eleven bodies were recovered from the blast site and two people died while undergoing treatment at a hospital,' the official said.
The explosion was so powerful that some of the workers were thrown nearly 100 metres away, eyewitnesses said.
The cause of the mishap would be known after examination by the technical experts, Narasimha, who visited the accident site along with state Labour Minister G Vivek Venkatswamy, told reporters.
Venkatswamy said 12 of the 34 injured people were critical and put on ventilator support in the hospitals. The respiratory system of these victims is under stress due to the burn injuries, he said.
The government is hopeful that the remaining 22 people will recover soon, he added.
Expressing grief over the tragedy, Prime Minister Narendra Modi conveyed condolences to those who lost their loved ones in the incident. He wished an early recovery to the injured.
In a post on 'X', he announced an ex gratia of Rs 2 lakh from the Prime Minister's National Relief Fund for the next of kin of the deceased and Rs 50,000 for the injured.
The company said it deeply mourns the loss of lives and extends heartfelt condolences to the families of the deceased. Asserting that the unit was fully insured, the firm assured all possible support to those affected.
Sigachi Industries also said production at its Hyderabad plant would be paused for around 90 days to restore affected equipment and structures.
In addition to the human impact, the incident also caused damage to certain ancillary equipment and civil structures within the facility, it said in a regulatory filing.
Y Nagi Reddy, Director General of the Telangana State Disaster Response and Fire Services, said it was suspected that the blast occurred in the drying unit of the plant. However, Inspector General of Police (Multizone) V Satyanarayana told reporters that it was a case of reactor explosion.
'Industrial experts are saying that during the drying process, or a handling process, the pressure could have built up, followed by the blasting of the material that led to the blasting of the entire building,' Reddy told reporters.
He said efforts were also on to search and rescue those trapped in the collapsed three-story building.
Satyanarayana said the impact of the blast was felt for about five km in the Pashamylaram area.
Chief Minister A Revanth Reddy expressed anguish over the incident and directed officials to take all steps to save the trapped workers and provide them advanced medical care, an official release said.
Meanwhile, the state government has also appointed a five-member committee headed by Chief Secretary Ramakrishna Rao to monitor the ongoing rescue efforts in the blast incident. The panel will also probe the incident.
Venkatswamy said the person in charge of the factory also lost his life in the accident, and 'there is nobody from the factory side to give us really what happened.'
After the incident, the district Collector and Superintendent of Police reached the spot within 30 minutes, he said.
He said a good ex gratia amount would be ensured to the kin of the deceased, and the government would also consider interim help to the affected families.
He said DNA tests were being conducted in hospitals to identify some of the deceased.
At least half a dozen bodies need to undergo DNA profiling to establish the identity, as they were charred beyond recognition, a Revenue Department official said.
Sigachi Industries Limited is a pharmaceutical company dedicated to pioneering advancements in Active Pharmaceutical Ingredients (APIs), Intermediates, Excipients, vitamin-mineral blends, and Operations and Management (O&M) services, according to the company's website.
Earlier, IGP (Multizone) Satyanarayana, quoting factory sources, said there were 150 people in the factory at the time of the blast, and 90 people were in the same area where the explosion occurred. He said the explosion occurred between 9.28 am and 9.35 am.
About ten firefighting engines were pressed into service, he said, adding the personnel of NDRF and SDRF were also engaged in the rescue operation.
(Only the headline has been reworked by India.com staff. Copy comes from an agency feed)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
an hour ago
- Indian Express
After probe report on financial irregularities, all but one clinical trials cancelled at Ahmedabad Hospital
When the investigation into the alleged financial irregularities in clinical trials at an Ahmedabad-based government hospital began, 10 trials were underway at the hospital while seven, for which agreements had been signed, were yet to begin. With the irregularities coming to light, all the clinical trials that were in their initial phases were shut down, while those that were yet to begin were cancelled, said a senior official of the Ahmedabad Municipal Corporation (AMC). As of now, only one clinical trial is underway at the Sheth Vadilal Sarabhai General Hospital, Medical Superintendent Dr Parul Shah confirmed with The Indian Express. Meanwhile, at least four to five doctors accused in the scam have returned the amount deposited in their bank accounts, said Dr Shah. 'We have sent the doctors notices that as per the report, we need to recover the money they received directly for the clinical trials. At least 4-5 doctors have already paid back the amount. The rest are also going to pay us back,' said Dr Shah. When asked if the hospital would conduct more trials in the coming days, an official said, 'We have decided to not do any clinical trials at the moment till all these irregularities are sorted out.' As reported by The Indian Express on July 1, a probe panel in Gujarat found financial irregularities in about 65 human clinical trials conducted at the hospital run by the AMC, where 15 doctors allegedly diverted at least Rs 1.87 crore directly to their personal accounts from 2021 — money that should have gone to the hospital first, according to a senior official. It has now also been learnt that the Drugs Controller General of India (DCGI) has asked the hospital not to conduct any more trials without proper standard operating procedures and permissions. The clinical trials that the hospital was conducting included those of drugs and formulations from 34 different pharmaceutical companies and clinical research companies (CROs), and were being managed by up to eight Site Management Organisations (SMOs). Of the 65 trials, a total of 48 had been completed, 10 were underway and seven were yet to begin, for which agreements had been signed. However, according to hospital officials, currently, only one trial is still underway. An official from the AMC Medical Education Trust (AMCMET) said, 'We had stopped most of the clinical trials that were in their initial phases before the investigation began. Only one trial is underway and we will complete that trial in the interest of the patients. No patients have had to suffer due to the financial irregularities.' Dr Shah said, 'The DCGI team that conducted its investigation here at the hospital said that the clinical trials themselves were conducted in a proper manner. Whatever discrepancies were there, were in the financial aspects. The trials were not compromised.' The DCGI, when it conducted its three-day investigation in May, asked the hospital to immediately stop the trials, form an ethics committee and get it vetted by the authorities if they wanted to conduct more trials, said sources. A total of 15 doctors were alleged to have siphoned off Rs 1.87 crore, proceeds from 58 clinical trials, into their personal bank accounts. Only Rs 10.63 lakh had been found to have been deposited in the account of the hospital. An inquiry committee found that a retired Medical Superintendent, an Associate Professor and 12 contractual doctors had been involved in the alleged scam
India Today
3 hours ago
- India Today
Same pills, smaller bills: Janaushadhi means savings
As Bihar moves closer to state elections, a strategic shift is underway in its rural healthcare approach, merging policy rollout with political March, the Centre announced that Primary Agricultural Credit Societies across India would operate Janaushadhi Kendras to expand access to affordable generic medicines. Bihar has now joined the ahead of the elections, the Muzaffarpur district administration selected seven PACS to open Janaushadhi outlets in its first phase, with one already licensed and six more in the These centres will make World Health Organisation-certified generic medicines available at prices 50–80 per cent lower than branded alternatives, making essential healthcare more affordable for rural of March 2025, more than 2,300 PACS across 34 states and Union Territories had been approved to operate Janaushadhi Kendras, raising key questions: how evenly are these centres distributed across India, and how much can people save?More kendras, more savingsAs of February 2025, the number of Janaushadhi Kendras operating across the country stood at 16,489, more than doubling from 6,306 outlets in 2019– consistent growth in presence has also led to a sharp rise in sales and consumer savings. In 2019–20, the scheme reported sales of Rs 433.61 crore with citizen savings estimated at Rs 2,500 crore. The following year, 2020–21, saw the number of kendras grow to 7,557, sales jump to Rs 665.83 crore, and estimated savings touch Rs 4,000 crore according to the Janaushadhi annual upward trend continued in 2021–22, with 8,610 kendras and Rs 5,400 crore in savings. By 2023–24, the number of centres increased to 12,616, through which people saved Rs 7,350 of the PriceMedicines that typically cost hundreds or thousands are available at a fraction of the price under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana. A price comparison across ten commonly used medicines and medical items shows just how significant the savings can instance, Glibenclamide, a common diabetes drug, is sold for just Rs 5.5 per strip under the scheme, compared to Rs 30 in regular pharmacies, offering a saving of around 82 per cent. A pulse oximeter, often used in respiratory care, an important machine after Covid-19, costs Rs 495 through Janaushadhi but sells for nearly Rs 1,599 in retail, a 69 per cent price cut. Budesonide inhalers used by asthma patients are available for Rs 123 compared to the market average of Rs acetate injections, often prescribed for prostate and breast cancer, cost Rs 1,800 under the scheme, down from the market price of Rs 3,453, a 48 per cent saving. Other drugs show a similar trend. The price gap spans across multiple therapeutic areas: diabetes, oncology, cardiovascular disease, respiratory care, and even surgical consumables, and offers a wide range of 2,047 generic medicines and 300 surgical items, all priced 50 per cent to 80 per cent lower than their branded counterparts.- Ends
India Today
3 hours ago
- India Today
Factory of fire: Inside Sigachi's trail of ignored alarms, regulatory gaps
A reactor blast at the Sigachi pharma plant in Telangana's Pashamylaram has killed at least 40 people, including workers, and has brought factories and industries under the spotlight. Was it a lapse in safety, a failure of oversight, or something more systemic? And in the aftermath, one question echoes loudest: Who is responsible?Sigachi Industries manufactures microcrystalline cellulose powder, a combustible and highly flammable dust used as a binder, disintegrant, filler, and lubricant in pharmaceutical records from the Telangana Fire Department show the same pharmaceutical plant was hit by a similar, serious fire in September 2019, caused by an electrical fault, resulting in losses exceeding Rs 1 crore. And Sigachi is not the only site in Pashamylaram where fire is frequent. Out of 99 incidents of industrial fire in Sanagareddy district in the past eight years, at least 23 were reported in this industrial complex at Pashamylaram. Pashamylaram hosts a tight cluster of high-risk chemical and pharmaceutical units, with over 60 plants involved in manufacturing bulk drugs, excipients like MCC, active pharmaceutical ingredients, and intermediates, many of which are prone to combustible dust and fire hazards. The area also houses critical infrastructure such as a zero liquid discharge, common effluent treatment plant, supporting sustainable wastewater management for these REACTSadvertisement"We are deeply anguished by the tragic accident at our Pashamylaram facility, which resulted in the loss of 40 valued team members and left over 33 injured. Our thoughts are with all those affected," Sigachi Industries said in a company added that, contrary to media reports, "the accident was not caused by a reactor explosion at the plant".It further stated, "Sigachi Industries Ltd has committed an ex-gratia compensation of 1 crore to the families of the deceased, while those injured will receive full medical and rehabilitation support. Our plant operations will remain temporarily suspended for approximately 90 days."Telangana's industrial zones - Jeedimetla, IDA Bollaram, Pashamylaram, and Patancheru — average one fire every two days, totalling nearly 190 incidents annually, or 1,522 over the past eight years. Just last year, the district collector, Valluru Kranthi, conducted inspections in the Pashamylaram Industrial Area, ordered the closure of Salubrious Industries, Vital Synthetics, and Venkar Chemical Limited plants for failing to meet fire safety was followed by a fire at Salubrious on February 13, caused by the management's neglect of mandatory safety protocols, the collector told local Synthetics, which produces drug intermediates, lacked essential fire safety equipment, including fire hydrants, portable extinguishers, and underground water storage tanks. The fire control board had previously issued notices to Vital Synthetics for FIRE NOC?advertisementComing to Sigachi, in the run-up to its November 2019 IPO, the company's red herring prospectus filed with SEBI admitted in Section 12 that it had not applied for several mandatory licenses and approvals. This included a fire no-objection certificate for its Telangana plant in the Pashamylaram Industrial Area, producing microcrystalline Red Herring Prospectus outlines a company's operations, finances, and risks ahead of an IPO, to gauge investor interest and provide transparency to potential State Disaster Response and Fire Services Director General Y Nagi Reddy told India Today that the building lacked a fire NOC for the current year - but also claimed that one wasn't required in this case, underlining a grey area regarding the applicability of fire safety regulations under the Telangana Fire Service Act, 1999, and the Factories Act, prospectus also disclosed that Sigachi lacked a pollution certificate for its Gujarat plant and a fire safety audit for Pashamylaram. There's no public record confirming if these were obtained NORMS FLOUTED AT SIGACHIUnder safety norms for industries handling combustible dust, the Factories Act mandates exhaust systems, enclosed and vented machinery, regular dust removal, fire hydrants, heat sensors, portable extinguishers, underground water tanks, and two outward-opening exits per Reddy said that Sigachi's Telangana unit had only a few inadequate fire extinguishers, likely installed after the 2019 fire. The ageing building lacked key safety features like fire alarms, heat sensors, and automatic shutdown systems, pointing to serious lapses under the Telangana Fire Service Act. He remarked that the fire department's safety audit was 'as good as non-existent,' stressing that the onus lies squarely on the company owner to maintain fire safety systems as per industrial there were structural safety issues, as there were no blast-resistant walls or roofs in processing areas. India Today's ground input confirmed improper containment of microcrystalline cellulose, a highly inflammable material prone to static electricity. No third-party safety inspections have been conducted in recent years, and outdated machinery continued to be used despite worker warnings about safety QUESTIONSTime and again, lax safety compliance has led to shutdowns in this fire-prone hub, raising a critical question: Why isn't a fire NOC mandatory in such high-risk zones? Reddy's conflicting remarks on Sigachi's fire NOC requirement highlight regulatory gaps and inconsistent enforcement of fire safety norms in high-risk industrial was not an accident - it was waiting to happen," said Rajanala Sai Yashwanth, the son of one of the deceased. His 55-year-old father, Rajanala Venkat Jagan Mohan, who had served at Sigachi Industries for 20 years, died in Monday's explosion. He stated that workers had repeatedly requested management to replace unsafe machinery, but these warnings were company management has been charged with culpable homicide amounting to murder, grievous harm, and attempted murder.- EndsMust Watch
